News

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado

Thursday, March 23, 2017

CU Boulder Study: Federally-Funded Laboratories and Institutions Have a $2.6 Billion Annual Impact in Colorado  

New Study Shows Biodesix’s VeriStrat Changes Treatment Decisions for Lung Cancer Patients; Reduces Over-Treatment at End of Life

Wednesday, March 22, 2017

BOULDER, Colo., March 22, 2017 (GLOBE NEWSWIRE) -- Biodesix®, Inc. announced today the results of a study demonstrating that the use of the VeriStrat® test for patients with non-small cell lung cancer (NSCLC) directly impacts physician treatment decisions in real-world clinical practice. In the study, use of the VeriStrat test resulted in an 89% decrease in ineffective treatments for patients who tested VeriStrat-Poor. A “decision impact” study demonstrates that a test changes the way patients are treated after test results are known. The decision impact study on VeriStrat was published in Current Medical Research and Opinion.  

InDevR Launches Next-Generation Software for the Cypher One™ System

Tuesday, March 21, 2017

BOULDER, Colo.--(BUSINESS WIRE)--InDevR, Inc., an innovative life science company dedicated to improving biopharmaceutical and vaccine manufacturing, today announced the global launch of the next-generation Cypher One™ 3.1 software to further enhance the functionality of the Cypher One™ automated hemagglutination (HA) and hemagglutination inhibition (HAI) interpretation instrument. 

ARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update

Tuesday, March 21, 2017

Westminster, CO, March 21, 2017 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the year ended December 31, 2016, and provided a business update.  

Study Results from Biodesix’s Immunotherapy Test Will Be Presented by Dr. Jeffrey Weber

Monday, March 20, 2017

Proteomic Test Identifies Sensitivity and Resistance to Immunotherapy in Cancer Patients 

Colorado BioScience Association links life science leaders to legislators at annual Capitol event

Friday, March 10, 2017

 

Biodesix® and Progenetics Announce Distribution Agreement for Israel

Thursday, March 09, 2017

BOULDER, Colo., March 09, 2017 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Boulder, CO, USA) and Progenetics LTD (Tel Aviv, Israel) announced today that they have entered into an international agreement where Progenetics will market and distribute kits for Biodesix’s GeneStrat® and VeriStrat® liquid biopsy tests for patients with non-small cell lung cancer (NSCLC). Both tests are now available for clinical use in Israel. 

PharmaJet® partners with Serum Institute to Launch Needle-Free MMR Vaccine

Tuesday, March 07, 2017

GOLDEN, Colo., March 7, 2017 /PRNewswire/ -- PharmaJet, the maker of innovative, needle-free injection technology, announced its partnership with Serum Institute of India, the world's largest vaccine manufacturer, is commercializing needle-free delivery of the MMR vaccine using the Stratis® 0.5mL needle-free injection system. 

VaxArray Flu Vaccine Potency Study Published in Vaccine

Tuesday, March 07, 2017

InDevR’s Study, “VaxArray Assessment of Influenza Split Vaccine Potency and Stability” published in Vaccine  

ARCA biopharma Announces 175th Patient Randomized into the GENETIC-AF Phase 2B/3 Clinical Trial

Monday, March 06, 2017

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 175th patient has been randomized into GENETIC-AF, a seamless design Phase 2B/3 clinical trial evaluating Gencaro™ (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF).